Dark Forest Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Dark Forest Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,060	Closed	-$13K	–	1569
2023 Q1	$13K	Buy	+1,060	New	+$12.5K	﹤0.01%	1008

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Dark Forest Capital Management's MACK Position: Q2 2023 in Review

Dark Forest Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2023, closing a stake of 1,060 shares — an estimated $13K sold.

Dark Forest Capital Management first reported a position in MACK in Q1 2023 and held it in 1 quarter. The position peaked at $13K in Q1 2023. 62 funds tracked by Wall St. Rank hold MACK as of Q2 2023.

Dark Forest Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Dark Forest Capital Management sold 1,060 Merrimack Pharmaceuticals, Inc. shares in Q2 2023, an estimated $13K.
Dark Forest Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
Dark Forest Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $13K in Q1 2023.
62 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2023.

Based on Dark Forest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.